Invivyd (IVVD) Competitors $0.75 -0.02 (-2.29%) As of 01:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IVVD vs. RGNX, MREO, ERAS, KMDA, VERV, TECX, ORIC, RAPP, RVNC, and ORGOShould you be buying Invivyd stock or one of its competitors? The main competitors of Invivyd include REGENXBIO (RGNX), Mereo BioPharma Group (MREO), Erasca (ERAS), Kamada (KMDA), Verve Therapeutics (VERV), Tectonic Therapeutic (TECX), ORIC Pharmaceuticals (ORIC), Rapport Therapeutics (RAPP), Revance Therapeutics (RVNC), and Organogenesis (ORGO). These companies are all part of the "pharmaceutical products" industry. Invivyd vs. REGENXBIO Mereo BioPharma Group Erasca Kamada Verve Therapeutics Tectonic Therapeutic ORIC Pharmaceuticals Rapport Therapeutics Revance Therapeutics Organogenesis Invivyd (NASDAQ:IVVD) and REGENXBIO (NASDAQ:RGNX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, community ranking, analyst recommendations and risk. Does the MarketBeat Community believe in IVVD or RGNX? REGENXBIO received 418 more outperform votes than Invivyd when rated by MarketBeat users. However, 86.21% of users gave Invivyd an outperform vote while only 65.44% of users gave REGENXBIO an outperform vote. CompanyUnderperformOutperformInvivydOutperform Votes2586.21% Underperform Votes413.79%REGENXBIOOutperform Votes44365.44% Underperform Votes23434.56% Do analysts prefer IVVD or RGNX? Invivyd currently has a consensus price target of $7.52, indicating a potential upside of 906.25%. REGENXBIO has a consensus price target of $31.63, indicating a potential upside of 224.03%. Given Invivyd's stronger consensus rating and higher possible upside, equities analysts plainly believe Invivyd is more favorable than REGENXBIO.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invivyd 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25REGENXBIO 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Does the media prefer IVVD or RGNX? In the previous week, REGENXBIO had 18 more articles in the media than Invivyd. MarketBeat recorded 25 mentions for REGENXBIO and 7 mentions for Invivyd. REGENXBIO's average media sentiment score of 0.48 beat Invivyd's score of 0.22 indicating that REGENXBIO is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Invivyd 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral REGENXBIO 3 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, IVVD or RGNX? Invivyd has a beta of 0.4, meaning that its share price is 60% less volatile than the S&P 500. Comparatively, REGENXBIO has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Do insiders & institutionals have more ownership in IVVD or RGNX? 70.4% of Invivyd shares are held by institutional investors. Comparatively, 88.1% of REGENXBIO shares are held by institutional investors. 25.4% of Invivyd shares are held by company insiders. Comparatively, 12.8% of REGENXBIO shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is IVVD or RGNX more profitable? Invivyd has a net margin of 0.00% compared to REGENXBIO's net margin of -283.19%. REGENXBIO's return on equity of -70.65% beat Invivyd's return on equity.Company Net Margins Return on Equity Return on Assets InvivydN/A -155.33% -114.88% REGENXBIO -283.19%-70.65%-41.68% Which has preferable earnings and valuation, IVVD or RGNX? Invivyd has higher earnings, but lower revenue than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInvivyd$36.69M2.44-$198.64M-$1.20-0.62REGENXBIO$156.72M3.12-$263.49M-$3.11-3.14 SummaryREGENXBIO beats Invivyd on 10 of the 19 factors compared between the two stocks. Get Invivyd News Delivered to You Automatically Sign up to receive the latest news and ratings for IVVD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IVVD vs. The Competition Export to ExcelMetricInvivydBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$89.61M$2.91B$5.33B$8.43BDividend YieldN/A1.68%5.21%4.11%P/E Ratio-0.3831.0026.8519.75Price / Sales2.44399.73388.74118.67Price / CashN/A168.6838.2534.62Price / Book0.463.226.764.50Net Income-$198.64M-$72.35M$3.23B$248.32M7 Day Performance6.11%4.46%1.71%0.48%1 Month Performance21.29%5.09%11.16%13.08%1 Year Performance-65.42%-27.12%17.17%7.36% Invivyd Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IVVDInvivyd2.9203 of 5 stars$0.75-2.3%$7.52+906.2%-65.4%$89.61M$36.69M-0.38100Earnings ReportRGNXREGENXBIO4.1978 of 5 stars$7.97+6.0%$31.63+296.8%-37.1%$399.43M$83.33M-1.58370Analyst RevisionMREOMereo BioPharma Group1.922 of 5 stars$2.50+3.7%$7.71+208.6%-26.3%$397.50M$1M-41.6740Positive NewsGap UpERASErasca3.6074 of 5 stars$1.39flat$4.83+247.7%-48.1%$393.77MN/A-1.67120Positive NewsKMDAKamada3.9356 of 5 stars$6.82-0.9%$14.67+115.1%+28.9%$392.01M$160.95M24.36360Analyst UpgradeAnalyst RevisionGap DownVERVVerve Therapeutics3.5199 of 5 stars$4.35+2.8%$25.75+492.0%-23.6%$387.77M$32.33M-1.77110Trending NewsAnalyst UpgradeAnalyst RevisionTECXTectonic Therapeutic3.615 of 5 stars$20.71+4.8%$72.40+249.6%N/A$386.68MN/A-3.52120Positive NewsORICORIC Pharmaceuticals4.4575 of 5 stars$5.41+6.5%$19.17+254.3%-34.0%$384.59MN/A-2.9780Positive NewsRAPPRapport Therapeutics1.5356 of 5 stars$10.47+2.1%$32.67+212.0%N/A$382.13MN/A-3.03N/ARVNCRevance Therapeutics1.8992 of 5 stars$3.65flat$8.39+129.7%N/A$381.02M$234.04M-1.89500News CoverageAnalyst ForecastORGOOrganogenesis4.0175 of 5 stars$2.98-2.6%$5.50+84.6%+8.7%$378.03M$482.04M-49.67950News CoveragePositive News Related Companies and Tools Related Companies RGNX Competitors MREO Competitors ERAS Competitors KMDA Competitors VERV Competitors TECX Competitors ORIC Competitors RAPP Competitors RVNC Competitors ORGO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IVVD) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredPrepare now for May 31 eventPrepare now for May 31 event Circle May 31 on your calendar This man grew up in a trailer in New Mexico. To...Stansberry Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invivyd, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invivyd With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IVVD Stock Free IVVD Stock Alerts